Search

Kiley Rae Prilliman

from Charlotte, NC
Age ~53
Get Report
Also known as:
Kiley R Prilliman, Kiley R Pillman, Kiley Prillman, Prilliman Kiley, N Kailey
Related to:
Sabrina M Goss, 44Alonzo Mccoy, 58Mary Kramer, 32Lexus Hughes, 31David O Hughes, 55
Connected to:
Andrew J Prilliman, 42Larissa Prilliman, 39Joseph L Prillmayer, 59Margie D Prillman, 57Kelly Prillwitz, 43Sergey V Prilutskiy, 51Ali H Prim, 56Aurea A Prim, 77Breanne A Prim, 45Buffie M Prim, 46

Kiley Prilliman Phones & Addresses

  • Charlotte, NC
  • 2010 Baltimore Rd APT F13, Rockville, MD 20851
  • 5249 Us Highway 277, Abilene, TX 79605 (325) 695-0861
  • Albuquerque, NM
  • 7150 Grand Ave, Dallas, TX 75223
  • San Diego, CA
  • Norman, OK
  • Oklahoma City, OK

Education

Degree: Associate degree or higher

Resumes

Resumes

Kiley Prilliman Photo 1

Senior Medical Writer

View page
Location:
723 The Pkwy, Richland, WA 99352
Industry:
Writing And Editing
Work:
Parexel Oct 2016 - Sep 2019
Senior Medical Writer - Early Phase
Veristat Oct 2016 - Sep 2019
Senior Medical Writer
Technical Resources International, Inc. Jul 2010 - Oct 2016
Medical Writer I and Ii and Iii
Prilliman Projects Jan 1, 2010 - Nov 1, 2012
Writer, Designer, and Scientific Consultant
Receptor Logic Ltd Dec 2007 - Nov 2009
Research Scientist
Education:
University of Oklahoma Health Sciences Center 1994 - 1999
Master of Science, Doctorates, Masters, Doctor of Philosophy, Microbiology, Immunology University of Oklahoma 1990 - 1994
Bachelors, Bachelor of Science, Microbiology, Chemistry Augusta University 1989 - 1990
Skills:
Immunology
Cell
Molecular Biology
Biotechnology
In Vivo
Medical Writing
Microbiology
Clinical Trials
In Vitro
Flow Cytometry
Animal Models
Assay Development
Cell Biology
Cell Culture
Life Sciences
Protein Chemistry
Clinical Development
Tissue Culture
Biochemistry
Vaccines
Scientific Writing
Drug Discovery
Clinical Research
Infectious Diseases
Immunohistochemistry
Molecular Cloning
Lifesciences
Cancer
Oncology
Virology
Protein Purification
Pcr
Science
Drug Development
Laboratory
Elisa
Genomics
Laboratory Skills
Pharmacology
Sop
Good Clinical Practice
Monoclonal Antibodies
Polymerase Chain Reaction
Communication
Management
Languages:
English
Spanish
Certifications:
Radical Candor (Blinkist Summary)
Tips For Writing Business Emails
Kiley Prilliman Photo 2

Kiley Prilliman

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Kiley Prilliman
Assistant Investigator
BAYLOR HEALTH CARE SYSTEM
Internal Medacine · General Hospital Home Health Care Services Nonresidential Construction · Management Consulting Services · General Hospital Home Health Care Services · Health and Allied Services, Nec, Nsk · Hospitals · Urgent Care Center · Family Doctor
2001 Bryan St STE 2200, Dallas, TX 75201
(972) 498-8650, (214) 820-0111, (214) 820-4242, (214) 820-4901

Publications

Us Patents

Anti-Interferon Alpha Monoclonal Antibodies And Methods For Use

View page
US Patent:
7888481, Feb 15, 2011
Filed:
Feb 6, 2009
Appl. No.:
12/367030
Inventors:
Jacques F. Banchereau - Dallas TX, US
Kiley Prilliman - Abilene TX, US
Virginia Pascual - Dallas TX, US
Anna Karolina Palucka - Dallas TX, US
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
C07K 16/00
A61K 39/395
US Classification:
5303881, 4241301, 4241331
Abstract:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Anti-Interferon Alpha Monoclonal Antibodies And Methods For Use

View page
US Patent:
8080638, Dec 20, 2011
Filed:
Feb 9, 2006
Appl. No.:
11/883961
Inventors:
Jacques Branchereau - Dallas TX, US
Kiley Prilliman - Dallas TX, US
Virginia Pascual - Dallas TX, US
Anna Karolina Palucka - Dallas TX, US
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
C07K 16/00
A61K 39/395
US Classification:
5303882, 5303892, 4241301, 4241331
Abstract:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Anti-Inteferon Alpha Monoclonal Antibodies And Methods For Use

View page
US Patent:
8333965, Dec 18, 2012
Filed:
Oct 4, 2011
Appl. No.:
13/252335
Inventors:
Jacques Banchereau - Dallas TX, US
Kiley Prilliman - Dallas TX, US
Virginia Pascual - Dallas TX, US
Anna Karolina Palucka - Dallas TX, US
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
A61K 39/395
A61K 38/00
C07K 16/00
C12P 21/08
US Classification:
4241301, 4241331, 4241451, 514 187, 5303871, 53038823
Abstract:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Anti-Interferon Alpha Monoclonal Antibodies And Methods Of Use

View page
US Patent:
20150166655, Jun 18, 2015
Filed:
Dec 16, 2014
Appl. No.:
14/571608
Inventors:
- DALLAS TX, US
Kiley PRILLIMAN - Rockville MD, US
Virginia PASCUAL - Dallas TX, US
Anna Karolina PALUCKA - Dallas TX, US
International Classification:
C07K 16/24
Abstract:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Anti-Interferon Alpha Monoclonal Antibodies And Methods For Use

View page
US Patent:
20140154239, Jun 5, 2014
Filed:
Dec 5, 2012
Appl. No.:
13/705289
Inventors:
Jacques Banchereau - Dallas TX, US
Kiley Prilliman - Dallas TX, US
Virginia Pascual - Dallas TX, US
Anna Karolina Palucka - Dalllas TX, US
International Classification:
C07K 16/24
US Classification:
4241331, 4241581
Abstract:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
Control profile
Kiley Rae Prilliman from Charlotte, NC, age ~53 Get Report